Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
about
Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsTangible resources for preparing patients for antiviral therapy for chronic hepatitis CAntidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysisQuinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory HypothesisAssociation of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C.Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C.A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C.Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?Recurrence of depressive disorders after interferon-induced depression.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Depression and antiviral response to interferon-based therapy for hepatitis C virus infectionPeginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in childrenManagement of Adverse Events During the Treatment of Chronic Hepatitis C Infection.Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo studyAn Aggravated Trajectory of Depression and Anxiety Co-morbid with Hepatitis C: A Within-groups Study of 61 Australian Outpatients.Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D).Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.A comparison of modified directly observed therapy to standard care for chronic hepatitis C.Effect of interferon-α on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study.Role of inflammatory cytokines in depression: Focus on interleukin-1β.Paeoniflorin ameliorates interferon-alpha-induced neuroinflammation and depressive-like behaviors in mice.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review.Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation.Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy.Changes in the NMR Metabolic Profile of Live Human Neuron-Like SH-SY5Y Cells Exposed to Interferon-α2.Pathogen-Host Defense in the Evolution of Depression: Insights into Epidemiology, Genetics, Bioregional Differences and Female Preponderance.Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis.Neuropsychiatric side-effects of interferon-alpha treatment: pathophysiology and therapeutic options.Depressive symptoms are frequent among drug users, but not associated with hepatitis C infection.Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.Clinimetrics and clinical psychometrics: macro- and micro-analysis.Major depression and suicide attempts in patients with liver disease in the United States.Acceptability of psychotherapy, pharmacotherapy, and self-directed therapies in Australians living with chronic hepatitis C.Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin.
P2860
Q26798477-EB77CF04-6AC3-46BD-9BF2-F5F6A5EA03EEQ26858962-6C2D2D2D-807D-42CC-B28A-91BF594A35F2Q26864986-B2194F36-CB08-4D19-88B6-72C7CCC839EAQ28607691-5DDFBDC3-2123-46F1-9E09-2714C067D78AQ30355874-9896A1CD-3DBA-4DAD-A41B-4A71CD3AC8E2Q31024615-DE03943E-9247-4581-892C-F9A364D1B2ABQ33413296-256BE32C-1204-445E-86C9-5B8AB8743F91Q33413353-D09099EE-3E79-4D68-8778-4FD9ECD1A81AQ33414941-51DD68AE-7D10-4936-BEB7-4EA80596B139Q33645706-AA7F6453-23A6-4EB7-8D67-62B014D87936Q33707679-3E22804A-F6F5-4C56-B7C5-AC8C13F8BB66Q34143327-D87A7ED5-1024-4A3C-A3CE-679DED9AE454Q34779005-40C53103-D5BF-4BEF-BA52-A310332DBD11Q34861058-11AC7550-3367-45BB-8556-9521F3B94919Q35082620-EBA49F74-4EDA-4BDE-BD42-7683914D50BAQ35535322-5446F3E5-6989-4C6A-8070-A804F3A9C7EFQ35749560-B9462EBD-3F24-401E-95EA-223246A79A90Q36364055-F83A7E4B-2E9F-405B-9659-679FB42C42A6Q36418455-A488E889-2196-414B-8EF2-47C6B615D4FFQ36493625-84C3CFBC-4B8B-4317-BAFE-2FB532659383Q36519135-F4FFBBC4-B51D-4D9C-BBB7-906383736371Q36997166-8DAAC833-7922-4628-9C39-F07B7A0D4290Q37136152-F5F76B90-4124-471B-8545-D4B9C13A5B16Q37593869-B8B6FACA-4546-470E-A896-FB34B0EC6BE1Q37702695-1E7DC844-AE98-4294-B20E-4288155D5249Q37846232-199CC286-B90C-4380-A155-08337045ED6FQ38098579-BD182121-224E-4A58-8FD0-6A1073578DA5Q38245124-EA86F5FC-6C8F-4A35-8FD8-F49603EE700DQ38264060-AF6E1E5F-61CE-405E-A5CC-D714900A8D86Q38821765-7DBE8FD2-2BE1-430D-8F89-A305B4FE6E88Q38954644-31772129-BA8B-4836-A99D-A549EF0B5B06Q39093985-CB96BEF4-3A40-4289-AF4B-8127D79E6138Q42029245-B0D372BF-375A-4967-9B9A-BC3B51EB88DFQ42210277-684DF035-B6A5-4F31-A08E-909E7D985D55Q43041286-9375FE49-EF89-44C4-A532-1F706BA47A4BQ43042527-D3F5305B-7441-4EE1-85F7-41E982FD6FC8Q43794534-6FE4BC70-AC5D-42C9-8C02-40B6F4505091Q45117603-23588A7A-C0E5-485D-A9BE-FB91C0A9C817Q45259841-A5B889FC-BA6A-405E-BDFD-C5F93B2A42CEQ45324202-6A19FB70-EC12-445D-9CB0-B14A8DC0D9FE
P2860
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@ast
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@en
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@nl
type
label
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@ast
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@en
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@nl
prefLabel
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@ast
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@en
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.
@nl
P2093
P2860
P50
P356
P1433
P1476
Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C
@en
P2093
Court Pedersen
Gunnar Norkrans
Kristine Mørch
Mads Rauning Buhl
NORDynamIC Group
Nina Langeland
Simon Hjerrild
P2860
P304
P356
10.1002/HEP.23699
P407
P577
2010-08-01T00:00:00Z